Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Melpomeni Toitou"'
The long non-coding RNA HOTAIR contributes to joint-specific gene expression in rheumatoid arthritis
Autor:
Muriel Elhai, Raphael Micheroli, Miranda Houtman, Masoumeh Mirrahimi, Larissa Moser, Chantal Pauli, Kristina Bürki, Andrea Laimbacher, Gabriela Kania, Kerstin Klein, Philipp Schätzle, Mojca Frank Bertoncelj, Sam G. Edalat, Leandra Keusch, Alexandra Khmelevskaya, Melpomeni Toitou, Celina Geiss, Thomas Rauer, Maria Sakkou, George Kollias, Marietta Armaka, Oliver Distler, Caroline Ospelt
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Abstract Although patients with rheumatoid arthritis (RA) typically exhibit symmetrical joint involvement, some patients develop alternative disease patterns in response to treatment, suggesting that different molecular mechanism may underlie disease
Externí odkaz:
https://doaj.org/article/69a704ad8e714379b5b6e4a46b31ca7a
Autor:
Lukas J.A.C. Hawinkels, Marieke F. Fransen, Charles P. Theuer, Andrew B. Nixon, James C.H. Hardwick, Cornelis F.M. Sier, Yingmiao Liu, Marieke C. Barnhoorn, Madelon Paauwe, Melpomeni Toitou, Bryan Koolmoes, Ricardo A. Angela, Maaike F.M. Koops, Mark J.A. Schoonderwoerd
Purpose:Endoglin is a coreceptor for TGFβ ligands that is highly expressed on proliferating endothelial cells and other cells in the tumor microenvironment. Clinical studies have noted increased programmed cell death (PD)-1 expression on cytotoxic T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3702f8d90d7f303861bc2911e5c0c708
https://doi.org/10.1158/1078-0432.c.6529037
https://doi.org/10.1158/1078-0432.c.6529037
Autor:
Lukas J.A.C. Hawinkels, Marieke F. Fransen, Charles P. Theuer, Andrew B. Nixon, James C.H. Hardwick, Cornelis F.M. Sier, Yingmiao Liu, Marieke C. Barnhoorn, Madelon Paauwe, Melpomeni Toitou, Bryan Koolmoes, Ricardo A. Angela, Maaike F.M. Koops, Mark J.A. Schoonderwoerd
Supplementary figures S1-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3675db8ca7b9e621d6ee63247eca66a1
https://doi.org/10.1158/1078-0432.22475297.v1
https://doi.org/10.1158/1078-0432.22475297.v1
Autor:
Lukas J.A.C. Hawinkels, Marieke F. Fransen, Charles P. Theuer, Andrew B. Nixon, James C.H. Hardwick, Cornelis F.M. Sier, Yingmiao Liu, Marieke C. Barnhoorn, Madelon Paauwe, Melpomeni Toitou, Bryan Koolmoes, Ricardo A. Angela, Maaike F.M. Koops, Mark J.A. Schoonderwoerd
Supplementary table 1 and 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0611569d69556fe3c23a48fb360ff6a7
https://doi.org/10.1158/1078-0432.22475294.v1
https://doi.org/10.1158/1078-0432.22475294.v1
Publikováno v:
Rheumatology (Oxford, England). 61(11)
Autor:
Andrew B. Nixon, Madelon Paauwe, Melpomeni Toitou, Charles P. Theuer, Marieke F. Fransen, Marieke C. Barnhoorn, Bryan Koolmoes, Lukas J. A. C. Hawinkels, James C. H. Hardwick, Maaike F.M. Koops, Ricardo A. Angela, Mark J A Schoonderwoerd, Yingmiao Liu, Cornelis F. M. Sier
Publikováno v:
Schoonderwoerd, M J A, Koops, M F M, Angela, R A, Koolmoes, B, Toitou, M, Paauwe, M, Barnhoorn, M C, Liu, Y, Sier, C F M, Hardwick, J C H, Nixon, A B, Theuer, C P, Fransen, M F & Hawinkels, L J A C 2020, ' Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy ', Clinical Cancer Research, vol. 26, no. 14, pp. 3831-3842 . https://doi.org/10.1158/1078-0432.CCR-19-2889
Clinical Cancer Research, 26(14), 3831-3842. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 26(14), 3831-3842. American Association for Cancer Research Inc.
Clinical Cancer Research, 26(14), 3831-3842. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 26(14), 3831-3842. American Association for Cancer Research Inc.
Purpose: Endoglin is a coreceptor for TGFβ ligands that is highly expressed on proliferating endothelial cells and other cells in the tumor microenvironment. Clinical studies have noted increased programmed cell death (PD)-1 expression on cytotoxic
Autor:
Haidong Huang, Naim Benhassen, Michael Steinheimer, Wolfgang Hohenforst-Schmidt, Chrysanthi Sardeli, Nikos Stalikas, Melpomeni Toitou, Paul Zarogoulidis
Publikováno v:
Therapeutics and Clinical Risk Management
INTRODUCTION The majority of cases of lung cancer are still diagnosed at a late stage. At this stage, palliative therapeutic options including nonspecific cytotoxic drugs, targeted therapy, or immunotherapy can be utilized. In 2016, immunotherapy was